Boston Scientific (BSX) Says CHAMPION-AF Trial Meets All Primary Endpoints [Yahoo! Finance]
Boston Scientific Corporation (BSX)
Last boston scientific corporation earnings: 4/29 06:30 am
Check Earnings Report
US:NYSE Investor Relations:
investors.bostonscientific.com
Company Research
Source: Yahoo! Finance
On March 29, 2026, Boston Scientific Corporation (NYSE:BSX) announced that its CHAMPION-AF clinical trial met all primary and secondary safety and efficacy endpoints. The study evaluated the WATCHMAN FLX device versus NOACs for stroke risk reduction in patients with non-valvular atrial fibrillation. The company said the device showed a 45% relative reduction in non-procedural bleeding risk and a 34% reduction when including procedural bleeding, while achieving non-inferiority on the primary efficacy endpoint. Results were presented at the American College of Cardiology's Annual Scientific Session and published in The New England Journal of Medicine. On March 26, 2026, Goldman Sachs lowered its price target on Boston Scientific Corporation (NYSE:BSX) to $93 from $98 and maintained a Buy rating, reflecting more moderate growth assumptions and a more risk-adjusted outlook. Goldman Sachs said positive data from CHAMPION-AF and increasing physician and investor confidence could support
Show less
Read more
Impact Snapshot
Event Time:
BSX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BSX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BSX alerts
High impacting Boston Scientific Corporation news events
Weekly update
A roundup of the hottest topics
BSX
News
- ?????????:2026???2036????408.0??????????????7.2% [CNET News]CNET News
- Global Interventional Oncology Industry Set to Grow by $1.18 Billion During 2026-2030 - AI-Assisted Imaging and Minimally Invasive Procedures Drive Interventional Oncology Expansion [Yahoo! Finance]Yahoo! Finance
- DEADLINE ALERT for BSX, EOSE, SLNO, and NKTR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of ShareholdersGlobeNewswire
- BOSTON SCIENTIFIC CORPORATION (BSX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Boston Scientific Corporation Investors of Upcoming DeadlineGlobeNewswire
- BSX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026GlobeNewswire
BSX
Earnings
- 2/4/26 - Beat
BSX
Sec Filings
- 4/2/26 - Form EFFECT
- 4/1/26 - Form 424B3
- 3/30/26 - Form S-4/A
- BSX's page on the SEC website